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ABSTRACT
Proteoglycan 4 (Prg4), known for its lubricating and protective actions in joints, is a strong candidate regulator of skeletal homeostasis
and parathyroid hormone (PTH) anabolism. Prg4 is a PTH-responsive gene in bone and liver. Prg4 null mutant mice were used to
investigate the impact of proteoglycan 4 on skeletal development, remodeling, and PTH anabolic actions. Young Prg4mutant and wild-
type mice were administered intermittent PTH(1–34) or vehicle daily from 4 to 21 days. Young Prg4mutant mice had decreased growth
plate hypertrophic zones, trabecular bone, and serum bone formation markers versus wild-type mice, but responded with a similar
anabolic response to PTH. Adult Prg4 mutant and wild-type mice were administered intermittent PTH(1–34) or vehicle daily from 16 to
22 weeks. Adult Prg4mutant mice had decreased trabecular and cortical bone, and blunted PTH-mediated increases in bone mass. Joint
range of motion and animal mobility were lower in adult Prg4 mutant versus wild-type mice. Adult Prg4 mutant mice had decreased
marrow and liver fibroblast growth factor 2 (FGF-2) mRNA and reduced serum FGF-2, which were normalized by PTH. A single dose of
PTH decreased the PTH/PTHrP receptor (PPR), and increased Prg4 and FGF-2 to a similar extent in liver and bone. Proteoglycan 4 supports
endochondral bone formation and the attainment of peak trabecular bone mass, and appears to support skeletal homeostasis
indirectly by protecting joint function. Bone- and liver-derived FGF-2 likely regulate proteoglycan 4 actions supporting trabeculae
formation. Blunted PTH anabolic responses in adult Prg4 mutant mice are associated with altered biomechanical impact secondary to
joint failure.  2012 American Society for Bone and Mineral Research.
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Introduction
Parathyroid hormone (PTH) has catabolic and anabolicactions in bone, depending on the mode of administration.
Continuous PTH administration induces bone resorption,
whereas intermittent PTH administration stimulates bone
formation.(1) Once-daily teriparatide [PTH(1–34)] injection is
currently the only U.S. Food and Drug Administration (FDA)-
approved anabolic agent for the treatment of osteoporosis, and
is under clinical investigation for the treatment of localized
osseous defects.(2,3) Whereas intermittent PTH(1–34) has proven
bone forming actions, the mechanismsmediating these anabolic
effects are poorly understood.
Osteoblasts and stromal cells are the predominant cells in
bone that express the PTH/PTH-related protein (PTHrP) receptor
(PPR). PTH signaling in osteoblastic cells has been shown to
regulate the expression of growth factors critical for PTH-induced
anabolic actions in bone.(4,5) Most notably, PTH anabolic actions
have been linked to insulin-like growth factor I (IGF-I) and basic
fibroblast growth factor 2 (FGF-2).(6–8) PTH rapidly upregulates
FGF-2 mRNA in cultured osteoblastic cells,(4) and intermittent
PTH administration increases IGF-I mRNA in bone in vivo.(5) IGF-I
and FGF-2 mutant mice have severely blunted to absent anabolic
responses to PTH.(6–8)
Proteoglycan 4 (Prg4), a novel PTH responsive gene in
bone,(9,10) is a strong candidate regulator of the anabolic actions
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of PTH. The Prg4 gene encodes an approximately 345-kD
proteoglycan, consisting of 1404 amino acids spanning 12 exons.
Prg4 is expressed in skeletal and nonskeletal tissues, with highest
levels of expression in articular joints, bone, and liver.(11,12) The
four isolated Prg4 protein products are secreted glycoproteins,
which have been implicated in the protection of articular joints,
expansion of hematopoietic progenitor cells, and regulation of
megakaryopoiesis. A proteoglycan 4 receptor has not been
identified.(12,13)
Loss-of-function mutations in Prg4 result in the human
autosomal recessive disorder camptodactyly–arthropathy–coxa
vara–pericarditis (CACP) syndrome, which is primarily character-
ized by precocious joint failure.(14) Similar to humans presenting
with the CACP syndrome, the Prg4 mutant mouse is afflicted by
early onset joint arthropathy.(12) Of interest, osteopenia has been
noted in microradiographs of joints from Prg4 mutant mice.(12)
Whereas studies have shown that Prg4 is endogenously
expressed in bone(11) and Prg4 is a PTH responsive gene in
the bone marrow in vivo and isolated osteoblastic cells in
vitro,(10) there have been no reported investigations of the
actions of proteoglycan 4 in bone. The purpose of this study was
to investigate the role of proteoglycan 4 as a regulator of skeletal
development, remodeling, and PTH anabolic actions. This
investigation of the Prg4 mutant mouse model provides for
the first study of proteoglycan 4 actions in bone.
Materials and Methods
C57BL6 wild-type mice
We harvested long bone (femur and tibia freed of soft tissue),
calvaria, bone marrow (flushed from a femur and tibia), and
whole liver from untreated 16-week-old C57BL6 wild-type mice
for gene expression analyses. In a PTH administration experi-
mental protocol, 8- to 16-week-old C57BL6 wild-type mice were
administered a single subcutaneous injection of recombinant
human PTH(1–34) (1mg/g) (Bachem; Torrence, CA, USA) or
vehicle (0.9% NaCl), euthanized 1, 4, 8, or 12 hours later,
and whole liver, calvaria, and long bone (femur and tibia freed
of soft tissue and growth plates sectioned) were harvested for
gene expression analyses. All animal studies were approved by
the University of Michigan Committee on the Use and Care of
Animals (UCUCA), and animals were maintained in accordance
with approved UCUCA research protocols.
Prg4 mutant (/) mice
Prg4 mutant (/) mice, generated by homologous recombina-
tion in 129Sv/Ev-derived embryonic stem cells, were generously
provided by MatthewWarman (Harvard).(12) Prg4/mice were
backcrossed from the 129Sv/Ev genetic background to the
C57BL6 genetic background. We used a PCR-based assay to
genotype the mice as previously described.(12)
Sixteen-week-old Prg4 / mice and wild-type (þ/þ)
littermates were administered a single subcutaneous injection
of recombinant human PTH(134) (1mg/g) (Bachem) or vehicle
(0.9% NaCl), euthanized 0 (no treatment control), 1, 4, 8, or
12 hours later, and bone marrow (flushed from a femur and tibia)
and whole liver were harvested for gene expression analyses.
In an intermittent PTH administration experimental protocol,
we administered 4-day-old Prg4 / and þ/þ littermate mice
once-daily subcutaneous injection of recombinant human
PTH(1–34) (50mg/kg) (Bachem) or vehicle (0.9% NaCl) control
for 17 days, from day 4 to 21. Prg4 mice treated from day 4 to 21
are referred to here as ‘‘young’’ Prg4mice. In another intermittent
PTH administration experimental protocol, we administered
16-week-old Prg4 / and þ/þ littermate mice once-daily
subcutaneous injection of recombinant human PTH(1–34)
(50mg/kg) (Bachem) or vehicle (0.9% NaCl) control for 6 weeks,
from 16 to 22 weeks. Prg4 mice treated from 16 to 22 weeks
are referred to here as ‘‘adult’’ Prg4 mice. We administered adult
Prg4 mice an intraperitoneal injection of calcein (Sigma-Aldrich,
St. Louis, MO, USA) (20mg/kg), dissolved in calcein buffer (0.15M
NaCl, 2% NaHCO3), 5 days and 2 days prior to euthanasia.
Twenty-four hours following the final PTH injection, we
euthanized the mice and harvested their tissues for analyses.
Quantitative real-time PCR
Bone marrow was directly flushed from a femur and tibia with
TRIzol reagent (Invitrogen, Carlsbad, CO, USA). Long bone,
calvaria, and whole liver were flash frozen, pulverized, and
homogenized in TRIzol reagent. Bone marrow stromal cell
(BMSC) cultures were washed three times with 1 PBS, and
TRIzol was directly applied to cultures. In each case, we isolated
RNA following the manufacturer’s protocol, and quantified the
total RNA. We synthesized double-stranded cDNA from 1.0mg of
RNA, using Random Hexamers (Applied Biosystems, Branchburg,
NJ, USA) and Multiscribe Reverse Transcriptase (Applied
Biosystems). cDNA was amplified using the TaqMan Universal
PCR Master Mix (Applied Biosystems) with TaqMan gene
expression–specific primers-probes (Applied Biosystems) for
proteoglycan 4 (Prg4), PTH/PTH-related protein receptor (PPR),
osteocalcin (OCN), collagen type II (col2), peroxisome prolif-
erator-activated receptor-gamma2 (PPARg2), insulin-like growth
factor I (IGF-I), and basic fibroblast growth factor 2 (FGF-2). We
used rodent glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Applied Biosystems) as an endogenous control.
Amplification was performed using the ABI Prism 7700 Sequence
Detection System (Applied Biosystems). Relative quantification
of data was carried out using the standard curve method or the
comparative CT method.(15)
Histomorphometry
Tibiae were fixed in 10% phosphate-buffered formalin for
48 hours at 48C. We decalcified tibiae from young mice in 10%
EDTA for 12 days at room temperature, and tibiae from adult
mice in 10% EDTA for 21 days at room temperature. Proximal
tibiae were embedded in paraffin, and 5mm serial frontal
sections were cut and stained. Hematoxylin and eosin (H&E)
stain was performed in all proximal tibia sections. Growth plate
height measurements were performed in H&E-stained proximal
tibia sections from young mice. Five measurements of the
proliferative zone and the hypertrophic zone were carried out in
the central two-thirds of the growth plate of each sample as
described by Yakar and colleagues.(16) Trabecular bone area
(BA/TA) analysis was carried out in the secondary spongiosa of
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H&E-stained proximal tibia sections from young and adult
mice. Proximal tibia sections from adult mice were stained for
tartrate resistant acid phosphatase (TRAP) using a commercial
leukocyte acid phosphatase assay kit (Sigma-Aldrich). The
number of TRAPþ multinucleated (three or more nuclei) cells
per millimeter bone perimeter trabecular bone were quantified
in the secondary spongiosa. Histomorphometric analysis of H&E-
stained and TRAP-stained proximal tibia sections was performed
using Image Pro Plus 5.1 software (Media Cybernetics, Silver
Spring, MD, USA) interfaced with a Nikon Eclipse E800 light/
epifluorescent microscope (Nikon Instruments, Melville, NY,
USA).
We fixed tibiae from adult mice in 10% phosphate-buffered
formalin for 48 hours at 48C, dehydrated them in graded ethanols
and xylene, and embedded them undecalcified in modified
methylmethacrylate. Serial frontal proximal tibia sections (4 and
8mm) were cut with vertical bed microtomes (Leica/Jung 2065
and 2165; Leica/Jung, Bannockburn, IL, USA) and affixed to slides
precoated with 1% gelatin solution. Four-micrometer (4-mm)
sections were stained by the von Kossa method with a
tetrachrome counterstain (Polysciences, Warrington, PA, USA),
and used for determining cellular endpoints. Eight-micrometer
(8-mm) unstained sections were used for analyzing calcein labels.
Bone histomorphometric data were collected semiautomatically
with a Nikon Eclipse E800 light/epifluorescent microscope and
the OsteoMeasure/Trabecular Analysis System (OsteoMetrics
Inc., Atlanta, GA, USA).
We began analysis of methylmethacrylate-embedded proxi-
mal tibia sections 200mm distal to the growth plate and 50mm
from the endocortical surfaces, including a 1200-mm (width)
800-mm (length) area. The number of osteoblasts per bone
perimeter (N.Ob/Pm) and osteoid surface (OS/BS) were assessed
in von Kossa–stained (4-mm) sections. Fluorochrome (calcein)-
based indices of bone formation including bone formation rate
(BFR/BS), mineral apposition rate (MAR), andmineralizing surface
(MS/BS) were analyzed in unstained (8-mm) sections. Bone
histomorphometry data are reported in accordance with
standardized nomenclature.(17)
Micro-CT
Femurs from young and adult mice were fixed in 10%
phosphate-buffered formalin for 48 hours at 48C, and stored
them in 70% ethanol. Femurs were scanned in water at an 18-mm
isotropic voxel resolution using eXplore Locus SP (GE Healthcare
Pre-Clinical Imaging, London, ON, Canada), and calibrated three-
dimensional images were reconstructed. Femur length was
measured, and cortical bone morphology was assessed in a
1-mm segment of mid-diaphysis with GE Medical Systems
MicroView v2.2 Advanced Bone Analysis Application software
(GE Healthcare Pre-Clinical Imaging). The center plane of the
1-mm segment was defined as the midpoint between the most
lateral point of the third trochanter and the most proximal point
of the distal epiphyseal growth plate. Cortical bone morphomet-
ric variables analyzed included total area (Tt.Ar), cortical area
(Ct.Ar), cortical area fraction (Ct.Ar/Tt.Ar), cortical thickness
(Ct.Th), marrow area (Ma.Ar), endocortical perimeter (Ec.Pm),
periosteal perimeter (Ps.Pm), and bone mineral density (BMD).
Femoral trabecular bone morphology and microarchitecture
were analyzed using the stereology function of GE Medical
Systems MicroView v2.2 Advanced Bone Analysis Application
software. Transverse CT slices were analyzed beginning 360mm
proximal to the distal growth plate and extending 1.98mm
proximally. Trabecular bone morphometric variables analyzed
included bone volume (BV/TV), trabecular number (Tb.N),
trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and
trabecular bone mineral density (Tb.BMD). Fixed thresholds of
1200 and 2000 Hounsfield Units for trabecular bone and cortical
bone, respectively, were used to discriminate mineralized tissue.
For samples from young mice, the location and length of the
region of interest was adjusted in proportion to femoral length.
Micro-CT data are reported in accordance with Bouxsein and
colleagues.(18)
Bone marrow stromal cell in vitro assays
Femur and tibia whole bonemarrowwas isolated from untreated
16-week-old Prg4 / and þ/þ littermate mice. Epiphyses were
sectioned, a 22G 0.5-inch needle was gently rotated into the
marrow cavity, and marrow cells were flushed with a-modified
minimum essential medium (a-MEM) (Invitrogen). Bone marrow
cells were disassociated, cells counts performed, and cells plated
at 3,000,000 cells/cm2 in 60-mm dishes in a-MEM supplemented
with 20% fetal bovine serum (FBS) (HyClone, Provo, UT, USA),
100U/mL penicillin, 100mg/mL streptomycin, 2mM glutamine,
and 10 nM dexamethasone (Sigma-Aldrich).
We isolated bone marrow stromal cells (BMSCs) (adherent
cells) without passage at day 5. Culture media and nonadherent
cells were aspirated, and BMSCs were washed, trypsinized, and
plated in a-MEM supplemented with 10% FBS, 100 U/mL
penicillin, 100mg/mL streptomycin, 2mM glutamine for assays.
Plating cell density was assay dependent. Each in vitro assay was
carried out at least 2 times.
In a cell-enumeration assay, we plated first-passage BMSCs in
24-well plates at 20,000 cells/cm2. Cultures were carried out in
triplicate and medium was changed every other day. Cell
counting was performed on days 1, 3, 5, 7, and 9 using trypan
blue dye and a hemacytometer.
We used a flow cytometry (FACS) bromodeoxyuridine (BRDU)
cell proliferation assay and a FACS Annexin V cell apoptosis assay
with first-passage BMSCs. BMSCs were plated at 20,000 cells/cm2
in duplicate and medium was changed at day 2. At day 4,
medium was aspirated and cells were washed with PBS. Cultures
were trypsinized, proliferation assessed via an APC BRDU Flow Kit
(BD Biosciences, San Jose, CA, USA), and apoptosis assessed
using an FITC Annexin V Apoptosis Detection Kit I (BD
Biosciences) according to the manufacturer’s instructions. BRDU
was administered to cultures 1 hour prior to harvest. Samples
were analyzed using a FACS Calibur Flow Cytometer (BD
Biosciences) and CellQuest Pro software (BD Biosciences).
In a von Kossa mineralization assay, we plated first-passage
BMSCs in 12-well plates at 100,000 cells/cm2. Cultures were
carried out in triplicate and medium was changed every other
day. Upon reaching confluency (day 4), cultures were treated
with mineralization medium (50mg/mL ascorbic acid, 10mM
b-glycerophosphate) for 14 days. At the end of the culture
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period, cells were fixed with 95% EtOH and stained with 5%
AgNO3 using the von Kossa method to detect mineralization.
(19)
In another experimental protocol, upon reaching confluency
(day 4) cultures were treated with mineralization medium and
human PTH(1–34) (10 nM) (Bachem, Torrance, CA, USA) or
vehicle (4mM HCl/0.1% BSA) treatment every other day for 7 or
14 days. At the end of the culture period, cells were fixed and
stained using the von Kossa method to detect mineralization.(19)
We used quantitative real-time PCR to evaluate genes
associated with cell differentiation. First-passage BMSCs were
plated in 12-well plates at 100,000 cells/cm2 and cultures were
carried out in duplicate; and medium was changed every other
day. Upon reaching confluency (day 4), cultures were treated
with mineralization medium (50mg/mL ascorbic acid, 10mM
b-glycerophosphate) for 5 days. At the end of the culture period,
cultures were harvested for osteocalcin mRNA expression
analysis. In another experimental protocol, first-passage BMSCs
were plated at 20,000 cells/cm2. At day 4, cultures were
harvested for collagen type II (col2) and PPARg2 mRNA
expression analysis.
Serum biochemical assays
We collected whole blood by cardiac puncture at euthanasia,
coagulated it at room temperature for 30minutes, centrifuged it,
and isolated the serum. Serum was stored at 808C until
assayed. Enzyme immunoassays were used to measure the
serum concentrations of tartrate-resistant acid phosphatase
form 5b (TRAP5b) (Immunodiagnostic Systems, Fountain Hills,
AZ, USA), propeptide of type I procollagen (P1NP) (Immunodi-
agnostic Systems), osteocalcin (OCN) (Biomedical Technologies,
Stoughton, MA, USA), intact PTH (Immutopics, San Clemente, CA,
USA), fibroblast growth factor-23 (FGF-23) (C-Term) (Immuto-
pics), insulin-like growth factor I (IGF-I) (R&D Systems, Minnea-
polis, MN, USA), and basic fibroblast growth factor-2 (FGF-2) (R&D
Systems). Serum calcium concentration was analyzed by a
colorimetric assay (Pointe Scientific, Canton, MI, USA). Assays
were performed according to the manufacturers’ instructions.
Joint range of motion and animal mobility
We assessed joint range of motion by measuring maximal hind
paw extension. Adult mice were anesthetized with isoflurane, the
right tibia was immobilized at 0 degrees on a protractor, and
maximal right hind paw extension was recorded.
We assessed animal mobility by monitoring spontaneous
exploratory behavior. Adult mice were placed in a 30-cm
40-cm chamber, divided into twelve 10-cm 10-cm grids.
Chamber walls were 10 cm in height, and constructed with a
firm transparent plastic material. Mice were placed in the
chamber and videotaped via a Flip Video HD camera (Cisco, San
Jose, CA, USA) for 1 minute. Videos were reviewed to score the
number of grids crossed and number of hindlimb stands. A
hindlimb stand was enumerated when the animal braced its
forepaws against the chamber wall and elevated its body with
the hindpaws. The spontaneous exploratory behavior study was
performed in the animal housing facility during the early
morning (1:00–2:00 a.m.). Mice were directly transferred from
their housed cage into the 12-grid chamber. The 12-grid
chamber was set up in a laminar flow hood positioned within
reaching distance of all housed cages to minimize stressing the
mice prior to assessing spontaneous exploratory behavior.
Statistical analysis
We performed unpaired t tests using GraphPad Instat Software
(GraphPad Software, San Diego, CA, USA). For comparison of
þ/þ PTH versus / PTH samples, values were expressed as
treatment over control prior to statistical analysis. Data are
presented as mean standard error of mean (SEM), and
statistical significance is p< 0.05 or lower. Statistical analysis
was carried out in consultation with the Center for Statistical
Consultation and Research (CSAR) at the University of Michigan.
Results
PTH regulates Prg4 mRNA in bone and liver
Quantitative real-time PCR studies assessing Prg4 mRNA
expression in long bone, calvaria, bone marrow, and whole
liver from untreated 16-week-old C57BL6 mice showed that Prg4
is expressed at highest levels in long bone and liver (Fig. 1A).
Based on the high relative expression of Prg4 mRNA in liver
(Fig. 1A), and because the liver expresses PPR (Fig. 1B),(20,21) we
assessed the impact of PTH on liver Prg4 mRNA expression. A
single subcutaneous injection of PTH(1–34) (1mg/g) in 16-week-
old C57BL6 wild-type mice significantly increased liver Prg4
mRNA (fourfold) 4 hours after injection, and liver Prg4 mRNA
remained significantly upregulated 8 and 12 hours after injection
(Fig. 1C). A single subcutaneous injection of PTH(1–34) also
increased Prg4 mRNA in calvaria and long bone (threefold)
4 hours after injection (Fig. 1D, E), showing that PTH regulates
Prg4 gene expression similarly in bone and liver. Whereas the
biologic role of PPR expression in the liver is unclear, the liver has
been shown to support skeletal homeostasis(16,22,23) and PTH
anabolic actions in the skeleton.(24,25)
Decreased bone and blunted PTH anabolic actions in
Prg4 / mice
Histomorphometric analysis of trabecular bone area (BA/TA) in
H&E-stained proximal tibia sections revealed marginally less
trabecular BA/TA in young Prg4/mice versusþ/þ littermates
(Fig. 2A, B), whereas adult Prg4 / mice had significantly
decreased trabecular BA/TA relative to þ/þ littermates (Fig. 2B,
C). PTH similarly increased trabecular BA/TA in young Prg4 þ/þ
and / mice, by 25% and 34%, respectively (Fig. 2A, B). PTH
treatment induced an 82% increase in trabecular BA/TA in adult
Prg4 þ/þ mice versus a 21% increase in / littermates
(p< 0.001) (Fig. 2B, C), showing that PTH anabolic actions
increasing trabecular BA/TA are blunted in adult Prg4 /mice.
Results from the micro-CT analysis of trabecular bone volume
(BV/TV) in the distal femur were similar to the histomorphometric
analysis of proximal tibia. Young and adult Prg4 / mice had
significantly less trabecular BV/TV versus age-matched þ/þ
littermates (Fig. 2D–F). The increase in trabecular BV/TV by PTH
was similar in young Prg4 þ/þ (130%) and / mice (149%)
(Fig. 2D, E). PTH treatment resulted in an 89% increase in
trabecular BV/TV in adult Prg4 þ/þ mice versus a 44% increase
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in / littermates (p 0.10) (Fig. 2E, F), revealing that PTH
actions increasing trabecular BV/TV are marginally reduced in
adult Prg4 / mice.
Further analysis of trabecular bone parameters in the distal
femur showed decreased trabecular bone mineral density
(Tb.BMD), trabecular number (Tb.N), and increased trabecular
separation (Tb.Sp) in both young and adult Prg4 / mice
(Table 1). Of interest, there was no difference in trabecular
thickness (Tb.Th) in Prg4 / versus þ/þ mice. PTH increased
Tb.BMD, Tb.Th, Tb.N, and decreased Tb.Sp similarly in young Prg4
/ versus þ/þ mice. Interestingly, the anabolic actions of PTH
increasing Tb.Th and Tb.BMD were significantly blunted in adult
Prg4/ versusþ/þmice. PTH induced a 39% increase in Tb.Th
in adult Prg4 þ/þ mice versus a 13% increase in / mice
(p< 0.05). Moreover, PTH treatment resulted in a 41% increase in
Tb.BMD in adult Prg4 þ/þ mice versus a 16% increase in /
mice (p< 0.05).
Micro-CT analysis of cortical bone in the femoral mid-shaft
showed no difference in cortical area fraction (Ct.Ar/Tt.Ar),
cortical thickness (Ct.Th), or cortical bone mineral density (BMD)
in young Prg4 / versus þ/þ mice. Adult Prg4 / mice
had decreased Ct.Ar/Tt.Ar and Ct.Th versus þ/þ littermates.
Further analysis of cortical bone parameters revealed that adult
Prg4 / mice had increased cortical marrow area (Ma.Ar) and
marginally increased endocortical perimeter (Ec.Pm) relative to
þ/þ littermates. Whereas PTH increased Ct.Ar/Tt.Ar, Ct.Th, and
BMD in adult Prg4 þ/þ mice, there was a lack of anabolic
response to PTH in adult Prg4 / mice (Table 1).
Altered growth plate in young Prg4 / mice
We assessed growth-plate morphology and height in proximal
tibiae from young Prg4 / and þ/þ mice to evaluate
alterations in endochondral bone formation. The proliferative
zone chondrocytes in Prg4 / mice were arranged in short
interrupted columns compared to long continuous columns in
Prg4 þ/þ mice (Fig. 3A). Whereas the proliferative zone height
was similar in Prg4 / versus þ/þmice, the hypertrophic zone
height and total growth plate height were reduced in Prg4 /
versus þ/þ mice (Fig. 3B–D). PTH increased the hypertrophic
zone height and total growth plate height similarly in Prg4 /
versus þ/þ mice (Fig. 3C, D). Measurements of femur length
showed no difference in longitudinal growth of long bones in
young Prg4 / versus þ/þ mice (Fig. 3E).
Reduced biochemical markers of bone formation in
young Prg4 / mice
We used serum biochemical assays to investigate alterations in
bone modeling and response to PTH in young Prg4 / mice.
Fig. 1. PTH regulation of Prg4 mRNA. (A, B) Untreated 16-week-old C57BL6 wild-type mice were euthanized, and long bone, calvaria, bone marrow, and
liver were harvested for gene expression analysis (n¼ 3/group). RNA was isolated and quantitative real-time PCR was performed to assess; (A)
proteoglycan 4 (Prg4) mRNA, and (B) PTH/PTHrP receptor (PPR) mRNA expression (standardized to GAPDH levels). Relative quantification of data was
determined using the standard curve method. (C–E) Eight- to 16-week-old C57BL6 wild-type mice were administered a single subcutaneous injection of
PTH(1–34) (1mg/g) or vehicle (VEH) (0.9% NaCl) control, euthanized 1, 4, 8, or 12 hours later, and whole liver, calvaria, and long bone were harvested for
gene expression analysis (n 5/group). RNA was isolated and quantitative real-time PCR was performed to assess Prg4mRNA expression (standardized to
GAPDH levels) in (C) liver, (D) calvaria, and (E) long bone. Relative quantification of data generated was carried out using the comparative CT method.
p< 0.001; p< 0.05 versus time-matched VEH. Data are expressed as mean SEM.
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Markers for bone formation, serum propeptide of type I
procollagen (P1NP) and serum osteocalcin (OCN), were
decreased in vehicle-treated Prg4 / versus þ/þ mice
(Table 2). PTH did not alter serum P1NP in Prg4 / or þ/þ
mice (Table 2). PTH increased serum OCN in Prg4 / mice, but
did not effect serum OCN in þ/þ mice (Table 2). There was no
difference in serum TRAP5b, a marker for bone resorption, in
control Prg4mice, and PTH increased serum TRAP5b in Prg4/
versus þ/þ mice similarly (Table 2).
Lack of differences in Prg4 / BMSCs
We performed BMSC in vitro assays to elucidate cell-intrinsic
differences in Prg4 / stromal/osteoblastic cells. There was no
difference in Prg4 / versus þ/þ BMSC numbers over time
(Fig. 4A), cell proliferation (Supplementary Fig. S1A), or cell
apoptosis (Supplementary Fig. S1B). There was no difference in
collagen type II (col2) and PPARg2 mRNA expression in
undifferentiated day 4 BMSC cultures (Fig. 4B, C), and OCN
mRNA expression was similar in day 9 differentiated BMSC
cultures (Fig. 4D), which suggests that BMSCs from Prg4 /
mice do not have alterations in differentiation. Similar minerali-
zation was present in day 7 and day 14 Prg4 / versus þ/þ
BMSC cultures (Fig. 4E, F) (Supplementary Fig. S1C-F), which
further suggests that BMSCs from Prg4 / mice do not have
intrinsic alterations in differentiation. Furthermore, PTH admin-
istration similarly decreased mineralization in day 7 and day 14
Prg4/ versusþ/þ BMSC cultures (Supplementary Fig. S1C–F),
which shows that BMSCs from Prg4 / and þ/þmice respond
similarly to PTH at the cellular level.
Similar bone remodeling in adult Prg4 /
and þ/þ mice
In order to elucidate whether differences in bone cell numbers or
activity mediate the osteopenic skeletal phenotype and blunted
anabolic response to PTH in adult Prg4 /mice, we performed
static cellular and dynamic histomorphometric analyses in the
Fig. 2. Trabecular bone area and volume analysis. (A,B,D,E) Four-day-old Prg4 mutant (/) and wild-type (þ/þ) mice were administered intermittent
PTH(1–34) (50mg/kg) or vehicle (VEH) (0.9% NaCl) subcutaneous injection daily for 17 days (‘‘young’’ mice). (B,C,E,F) Sixteen-week-old Prg4 / and þ/þ
mice were administered intermittent PTH(1–34) (50mg/kg) or vehicle (VEH) (0.9% NaCl) control subcutaneous injection daily for 6 weeks (‘‘adult’’ mice).
Femur and tibia were harvested at time of euthanasia. (A–C) Histomorphometric analysis of trabecular bone area (BA/TA) in proximal tibia (secondary
spongiosa) of young (n 11/group) and adult (n 13/group) mice. Representative images (4 ) of H&E stained proximal tibial sections from, (A) young
and (C) adult mice. (B) Trabecular BA/TA in the proximal tibia (secondary spongiosa). p< 0.01 versus þ/þ VEH; p< 0.001 versus / VEH; þp< 0.001
versusþ/þ VEH; þþp< 0.05 versusþ/þ VEH; þþþp< 0.01 versus / VEH andþ/þ PTH. (D–F) Micro-CT analysis of distal femur trabecular bone volume
fraction (BV/TV) in young (n 11/group) and adult (n¼ 8/group) mice. Representative reconstructed micro-CT cross-sectional images of distal femur from
(D) young and ( F) adult mice. Representative images were captured in the distal femur, extending 0.5mm proximally from where analysis was initiated.
(E) Distal femur trabecular BV/TV. p< 0.001 versus þ/þ VEH; p< 0.05 versus þ/þ VEH; p< 0.001 versus / VEH; þp< 0.01 versus þ/þ VEH;
þþp< 0.01 versus þ/þ VEH; þþþp< 0.05 versus / VEH. For comparison of þ/þ PTH versus / PTH samples, values were expressed as treatment
over control prior to statistical analysis. Data are expressed as mean SEM.
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secondary spongiosa of proximal tibiae from adult Prg4 mice
(Fig. 5A–H). There were no differences in numbers of osteoblasts
per bone perimeter (N.Ob/B.Pm), osteoclastic TRAPþ cells
per bone perimeter, osteoid surface (OS/BS), bone formation
rates (BFR/BS), or mineral apposition rates (MAR) in control
Prg4 / versus þ/þ mice, and PTH increased N.Ob/B.Pm,
TRAPþ cells, OS/BS, BFR/BS, and MAR in Prg4 / versus þ/þ
mice similarly (Fig. 5A–H). These findings indicate that
trabecular bone cell numbers, bone formation, and bone
mineralization are unaffected by lack of proteoglycan 4 in the
mature remodeling skeleton. Moreover, serum biochemical
assays showed no differences in markers for bone turnover
or mineral homeostasis in adult Prg4 / mice (Supplementary
Fig. S2).
Restricted joint range of motion and decreased mobility
in adult Prg4 / mice
Based on reports that adult Prg4 / mice have failing articular
joints(12) with significant loss of cartilage structure, stiffness, and
frictional properties,(26) we investigated changes in the joints of
Prg4 / mice, which could contribute to the osteopenic
skeletal phenotype and blunted PTH anabolic response in adult
Prg4 / mice. Maximal hind paw extension was assessed as a
measure of joint range of motion (Fig. 6A, B), and spontaneous
exploratory behavior was monitored to evaluate animal mobility
(Fig. 6C, D). Maximal hind paw extension was limited to 115
degrees in Prg4/mice compared to 170 degrees inþ/þmice
(Fig. 6A, B). The scoring of spontaneous exploratory behavior in a
Table 1. Femur Micro-CT Analysis
þ/þ VEH þ/þ PTH / VEH / PTH
Young Prg4 mice (n 11/gp)
Trabecular bone
BV/TV (%) 8.50 0.57 18.8 1.64 7.00 0.39 17.5 1.83þþþ
Tb.Th (mm) 27.7 0.64 36.5 1.21 26.6 0.32 33.3 1.55þþþ
Tb.Sp (mm) 309 18.2 167 11.5 365 19.0 177 20.0þþþ
Tb.N (mm1) 3.04 0.15 5.07 0.29 2.62 0.13 5.11 0.38þþþ
Tb.BMD (mg/cc) 134 3.54 191 9.19 123 3.38 187 9.65þþþ
Cortical bone
Tt.Ar (mm2) 1.37 0.07 1.32 0.04 1.35 0.04 1.26 0.04
Ct.Ar (mm2) 0.37 0.03 0.33 0.02 0.34 0.01 0.31 0.02
Ct.Ar/Tt.Ar (%) 26.6 0.82 24.5 1.02 25.2 0.60 24.2 0.98
Ct.Th (mm) 96.1 5.43 86.2 5.09 89.5 3.05 83.3 4.54
Ma.Ar (mm2) 1.00 0.04 0.99 0.02 1.01 0.03 0.96 0.02
Ec.Pm (mm) 3.61 0.08 3.61 0.04 3.62 0.05 3.53 0.04
Ps.Pm (mm) 4.20 0.11 4.14 0.07 4.17 0.06 4.05 0.06
BMD (mg/cc) 235 8.52 207 10.5 219 7.42 208 9.01
Adult Prg4 mice (n¼ 8/gp)
Trabecular bone
BV/TV (%) 10.7 0.87 20.3 2.40 (89%) 6.79 0.57 9.78 0.90þ (44%)
Tb.Th (mm) 32.5 0.61 45.0 2.99 (39%) 29.9 1.70 33.9 1.50# (13%)
Tb.Sp (mm) 283 21.9 188 18.7 (34%) 424 29.9 320 24.5þ (25%)
Tb.N (mm1) 3.28 0.23 4.49 0.36 (37%) 2.26 0.13 2.88 0.23þ (28%)
Tb.BMD (mg/cc) 197 11.8 278 19.3 (41%) 168 9.42 184 9.85þ,# (16%)
Cortical bone
Tt.Ar (mm2) 1.74 0.03 1.94 0.05 (12%) 1.80 0.03 1.88 0.04# (4.1%)
Ct.Ar (mm2) 0.88 0.01 1.02 0.02 (17%) 0.83 0.02 0.86 0.02## (3.7%)
Ct.Ar/Tt.Ar (%) 50.5 0.66 52.7 0.64 (4.2%) 46.1 0.88 45.9 0.37## (0.3%)
Ct.Th (mm) 221 3.06 246 3.15 (11%) 202 5.34 204 3.52### (1.3%)
Ma.Ar (mm2) 0.86 0.02 0.92 0.03 (7.2%) 0.97 0.02 1.02 0.02 (4.4%)
Ec.Pm (mm) 3.50 0.05 3.63 0.07 (3.6%) 3.61 0.03 3.69 0.04 (2.1%)
Ps.Pm (mm) 4.89 0.05 5.15 0.09 (5.4%) 4.91 0.06 4.97 0.05 (1.3%)
BMD (mg/cc) 511 9.46 562 14.2 (10%) 483 15.0 491 6.14# (1.6%)
gp¼group; VEH¼ vehicle; PTH¼parathyroid hormone; BV/TV¼bone volume; Tb.Th¼ trabecular thickness; Tb.Sp¼ trabecular separation; Tb.N¼ tra-
trabecular number; Tb.BMD¼ trabecular bone mineral density; Tt.Ar¼ total area; Ct.Ar¼ cortical area; Ct.Ar/Tt.Ar¼ cortical area fraction; Ct.Th¼ cortical
thickness; Ma.Ar¼marrow area; Ec.Pm¼ endocortical perimeter; Ps.Pm¼ periosteal perimeter; BMD¼ bone mineral density.
Data are expressed as mean SEM. Percentage increase over control analysis is presented in parenthesis.
p< 0.05 versus þ/þ VEH; p< 0.01 versus þ/þ VEH; p< 0.001 versus þ/þ VEH; þp< 0.05 versus / VEH; þþp< 0.01 versus /
VEH; þþþp< 0.001 versus / VEH; #p< 0.05 versus þ/þ PTH; ##p< 0.01 versus þ/þ PTH,
###p< 0.001 versus þ/þ PTH.
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12-grid chamber showed that Prg4 / mice crossed fewer
grids and stood on their hindlimbs fewer times than þ/þ
littermates (Fig. 6C, D) (Supplementary Video S3A,B). Because
the adult Prg4 / mice do not display gross signs of
muscle weakness, pain, or neurological deficits it is likely that
that the reduced animal mobility is attributed to compromised
joint structure and function(12,26) (Fig. 6A, B). The decreased
joint range of motion and animal mobility showed by adult Prg4
/ mice suggests that skeletal loading is altered in Prg4 /
mice.
Reduced liver IGF-I and FGF-2 and marrow FGF-2 mRNA
normalized by PTH in Prg4 / mice
We isolated bone marrow and whole liver from adult Prg4 mice
to assess basal gene expression and the impact of 6 weeks daily
PTH treatment on PPR, IGF-I, and FGF-2 mRNA expression.
Marrow PPRmRNAwas similar in control adult Prg4/ andþ/þ
mice (Table 3), which suggests that similar numbers of PPR
expressing osteoblastic cells are present in the marrow of adult
Prg4 / and þ/þ mice. Liver PPR mRNA was decreased in
control adult Prg4 / versus þ/þ mice (Table 3). It has been
reported that hepatocytes are the predominant PPR-expressing
cells in the liver.(21)
We assessed IGF-I mRNA expression in marrow and liver
because marrow-derived IGF-I and liver-derived IGF-I have been
shown to independently support skeletal homeostasis(16,22,23)
and PTH skeletal anabolism.(24,25) Stromal/osteoblastic cells
express IGF-I locally in the bone marrow mediating autocrine/
paracrine signaling,(27,28) and the liver secretes IGF-I into the
circulation facilitating endocrine signaling in bone.(29)
Unexpectedly, PTH significantly decreased marrow IGF-I
mRNA in adult Prg4þ/þmice and marginally decreased marrow
IGF-I mRNA in adult Prg4 / mice (Table 3). Although it has
been reported that intermittent PTH increases IGF-I mRNA
expression in bone matrix devoid of bone marrow,(5,30) we
are unaware of prior studies that measured the effect of
intermittent PTH on marrow IGF-I mRNA. Adult Prg4 / mice
had reduced liver IGF-I mRNA, and PTH normalized liver IGF-I
mRNA in Prg4 / mice to þ/þ levels (Table 3). The decreased
liver IGF-I mRNA in control adult Prg4 / mice suggests that
liver Prg4 may be important for IGF-I expression in the liver.
We assessed FGF-2 mRNA as another critical regulator of
skeletal remodeling(31) and PTH anabolic actions.(8,32) Adult Prg4
Fig. 3. Tibial growth plate and femur length analysis in young mice. (A–E) Four-day-old Prg4mutant (/) and wild-type (þ/þ) mice were administered
intermittent PTH(1–34) (50mg/kg) or vehicle (VEH) (0.9% NaCl) control subcutaneous injection daily for 17 days (‘‘young’’ mice). (A–D) Tibial growth plate
morphology and height were evaluated in H&E-stained proximal tibia sections from young Prg4/ versusþ/þmice (n 11/group). (A) Representative
images (40 ) of tibial growth plate from young Prg4/ versusþ/þmice. (B) Proliferative zone height. (C) Hypertrophic zone height. p< 0.001: versus
þ/þ VEH; p< 0.05: versus þ/þ VEH; p< 0.01: versus / VEH. (D) Total growth plate height. p< 0.05: versus þ/þ VEH; p< 0.05: versus þ/þ VEH;
p< 0.05: versus / VEH. (E) Femur length measurements performed via reconstructed micro-CT images of young Prg4 femurs (n 11/group).
Table 2. Serum Biochemical Analyses
þ/þ VEH þ/þ PTH / VEH / PTH
Young Prg4 mice (n¼ 9/gp)
P1NP (ng/mL) 584.32 43.50 580.41 30.44 377.30 35.64 388.13 35.31
OCN (ng/mL) 190.11 21.23 213.98 20.30 135.21 15.16 295.40 47.62þþ
TRAP5b (U/L) 18.52 2.06 24.30 1.13 15.09 1.51 21.19 1.61þ
Data are expressed as mean SEM.
gp¼ group; VEH¼ vehicle; PTH¼ parathyroid hormone.
p< 0.05 versus þ/þ VEH; p< 0.01 versus þ/þ VEH; þp< 0.05 versus / VEH; þþp< 0.01 versus / VEH.
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/ mice had lower marrow and liver FGF-2 mRNA than þ/þ
mice (Table 3), which implies that Prg4 supports FGF-2 gene
expression in marrow and liver. PTH increased marrow and liver
FGF-2 mRNA in adult Prg4 / mice to þ/þ levels (Table 3).
Reduced serum FGF-2 normalized by PTH in Prg4 / mice
We assayed serum IGF-I and FGF-2 in adult Prg4 / and þ/þ
mice to determine if alterations in Prg4 / marrow and liver
mRNA expression resulted in changes in the concentration of
circulating proteins. There was no difference in serum IGF-I in
adult Prg4 / and þ/þ mice (Table 4), which suggests that
the reduced liver IGF-I mRNA expression in Prg4 / mice is
sufficient to support normal levels of circulating IGF-I. In contrast,
adult Prg4 / mice had lower serum FGF-2 levels, and PTH
increased serum FGF-2 in Prg4 /mice to þ/þ levels (Table 4).
The reduced serum FGF-2 correlated with decreased liver
and marrow FGF-2 mRNA in adult Prg4 / mice, which were
normalized to þ/þ levels by PTH. Whereas circulating IGF-I has
been shown to be secreted primarily by the liver (75% to 80%),(29)
the source of circulating FGF-2 is unclear. Based on quantitative
real-time PCR showing comparable FGF-2 mRNA expression in
bone marrow and liver (data not shown), we speculate that
decreased circulating FGF-2 levels in adult Prg4 / mice are
attributed to both decreased marrow and liver FGF-2 mRNA
expression.
PTH alters gene expression similarly in bone marrow
and liver
Because PTH regulates Prg4 mRNA expression similarly in bone
and liver (Fig. 1C–E), we used single PTH injection studies to
elucidate whether Prg4 regulates the expression of several
critical PTH-responsive osteogenic genes in bone and liver. PTH
decreased marrow PPR mRNA at 1 hour and increased marrow
PPR mRNA 8hours after injection similarly in 16-week-old Prg4
/ and þ/þ mice (Fig. 7A). PTH decreased liver PPR mRNA
4hours after injection similarly in Prg4 / and þ/þ mice (Fig.
7D). The finding that PTH similarly downregulates PPR mRNA in
bone marrow and liver suggests that proteoglycan 4 does not
modify PTH binding and signaling at the PPR receptor in bone or
liver.
Although intermittent PTH treatment has been reported to
increase IGF-I mRNA expression in bone matrix in vivo,(5,30) little
is known regarding the temporal effects of PTH on IGF-I mRNA
expression. Marrow IGF-I mRNA was decreased 4 hours after PTH
injection in Prg4þ/þmice. Twelve hours following PTH injection,
marrow IGF-I mRNAwas significantly increased in Prg4þ/þmice.
PTH did not significantly alter marrow IGF-I mRNA in Prg4/ or
liver IGF-1 mRNA expression in Prg4/ orþ/þmice (Fig. 7B, E).
Single PTH injection significantly increased marrow and liver
FGF-2 mRNA in Prg4 / and þ/þ mice at 1 hour (Fig. 7C, F).
These findings were consistent with prior studies that showed
FGF-2 is an early immediate PTH-responsive gene in bone.(4)
Consistent with control adult Prg4 /mice (Table 3), control
16-week-old Prg4 / mice (Fig. 7A, B) had similar marrow PPR
and IGF-I mRNA levels compared to age-matched þ/þ mice.
Whereas control adult Prg4 / mice had decreased marrow
FGF-2 mRNA (Table 3), marrow FGF-2 mRNA was similar in
control 16-week-old Prg4 / versus þ/þ mice (Fig. 7C). This
finding indicates that decreased marrow FGF-2 mRNA in adult
Prg4 / mice is likely secondary to changes with age in the
adult Prg4 / mice. Although there are no known studies
Fig. 4. Bone marrow stromal cell (BMSC) in vitro osteoblastogenesis assays. (A–F) Untreated 16-week-old Prg4 mutant (/) and wild-type (þ/þ) mice
were euthanized, femoral and tibial bone marrow was harvested, and BMSCs were isolated for in vitro osteoblastogenesis assays. (A) Cell numbers over
time in BMSC cultures (n 6/group). (B) Collagen type II (col2) mRNA expression was assessed as a marker of chondrogenic potential in day 4 BMSC
cultures (n 6/group). (C) Peroxisome proliferator-activated receptor-gamma2 (PPARg2) mRNA expression was assessed as a marker of adipogenic
potential in day 4 BMSC cultures (n 6/group). (D) Osteocalcin (OCN) mRNA expression was assessed as a marker of osteoblast differentiation in day 9
BMSC cultures (n 10/group). RNA was standardized to GAPDH levels and relative quantification of data generated was determined using the standard
curvemethod. (E) Representative images of day 14 BMSC von Kossamineralization cultures. ( F) Mineralization area per well in day 14 BMSC cultures (n 6/
group). In vitro assays were carried out at least two times with similar results. Data are expressed as mean SEM.
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reporting the impact of skeletal loading/unloading on FGF-2
mRNA expression in bone, it is possible that altered skeletal
loading in Prg4 mutant mice may secondarily mediate the
decreased marrow FGF-2 mRNA.
Similar to control adult Prg4 / mice (Table 3), control
16-week-old Prg4 /mice (Fig. 7D–F) had decreased liver PPR,
IGF-I, and FGF-2 mRNA versus age-matched control þ/þ mice.
These consistent gene expression findings in the liver of adult
Prg4 / mice and 16-week-old Prg4 / mice indicate that
liver Prg4 supports physiologic PPR, IGF-I, and FGF-2 gene
expression in the liver.
Discussion
The four Prg4 protein products—lubricin, superficial zone
protein (SZP), hemangiopoietin (HAPO), and megakaryocyte
stimulating factor (MSF)—are secreted glycoproteins that have
been implicated in the protection of articular joints, support of
hematopoietic progenitor cells, and regulation of megakaryo-
poiesis. Although studies report that proteoglycan 4 has diverse
biologic actions, proteoglycan 4 receptors have not been
identified and receptor sites are unknown.(12,13) Although most
studies of Prg4 have focused on the role of the Prg4 gene product
Fig. 5. Proximal tibia bone cell numbers and activity. (A–H) Sixteen-week-old Prg4mutant (/) andwild-type (þ/þ) mice were administered intermittent
PTH(1–34) (50mg/kg) or vehicle (VEH) (0.9%NaCl) control subcutaneous injection daily for 6 weeks (‘‘adult’’ mice). Tibiae were isolated from adult Prg4/
and þ/þ mice for histomorphometric analysis of bone cell numbers and activity. (A–C) Histomorphometric analysis of von Kossa–stained
(with tetrachrome counterstain) proximal tibia sections was performed to assess osteoblast number per bone perimeter (N.Ob/B.Pm) and osteoid
surface (OS/BS) in the secondary spongiosa. (A) Representative images (40 ) of von Kossa–stained proximal tibia secondary spongiosa. (B) Osteoblast
numbers (n 10/group). p< 0.001 versus þ/þ VEH; p< 0.01 versus / VEH. (C) Osteoid surface (n 10/group). p< 0.05 versus þ/þ VEH; p< 0.05
versus / VEH. (D,E) TRAPþ cell enumeration was carried out in proximal tibia sections to assess osteoclast numbers per bone perimeter in the
secondary spongiosa. (D) Representative images (40 ) of TRAP-stained proximal tibia secondary spongiosa. (E) TRAPþ cell number per bone perimeter
(n 8/group). p< 0.05 versusþ/þ VEH; p< 0.01 versus/ VEH. ( F–H) Dynamic histomorphometric analysis of calcein-labeled proximal tibia sections
was performed to assess bone formation rates (BFR/BS) and mineral apposition rates (MAR) in the secondary spongiosa. ( F) Representative images (40 )
of dual calcein labels in proximal tibia secondary spongiosa. (G) Bone formation rate (n 8/group). p< 0.01 versusþ/þ VEH; p< 0.01 versus/ VEH.
(H) Mineral apposition rate (n 8/group). p< 0.01 versus þ/þ VEH; p< 0.01 versus / VEH. Data are expressed as mean SEM.
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lubricin and joint function, we hypothesized that proteoglycan 4
also plays a role in skeletal development and remodeling based
upon Prg4 expression in bone(11) and the noted osteopenic
phenotype in the Prg4 mutant mouse.(12) Furthermore, our
findings that Prg4 is a PTH-responsive gene in bone(10) lead us to
speculate that proteoglycan 4 supports the anabolic actions of
PTH in the skeleton.
Lubricin and SZP are expressed locally in the synovial joints by
synoviocytes and superficial zone articular chondrocytes, having
lubricating and protective effects.(12,33) Whereas the source of
HAPO and MSF is unknown, based on studies that implicate
HAPO and MSF in the regulation of hematopoiesis(13,34) and
demonstration of high Prg4 expression in liver and bone(11)
(major sites of hematopoiesis), it is likely that both liver and bone
act as considerable sources of proteoglycan 4. The novel finding
that Prg4 is a PTH-responsive gene not only in bone but also liver
implies that both marrow- and liver-derived proteoglycan 4 are
candidate regulators of skeletal remodeling and the anabolic
actions of PTH.
The finding that young Prg4 mutant mice have decreased
trabecular bone suggests that proteoglycan 4 plays a role in
endochondral bone formation. The decreased height of the
growth plate hypertrophic zone in young Prg4 mutant mice
suggests that proteoglycan 4 regulates growth plate chondro-
cyte maturation,(35) which could have implications for endo-
chondral cartilage ossification in developing long bone. Similar
femoral length in young Prg4 mutant and wild-type mice
indicates that abnormalities in the growth plates of Prg4 mutant
mice do not impact long bone longitudinal growth.
Although there were reduced numbers of trabeculae and
increased trabecular separation in both young and adult Prg4
mutant versus wild-type mice, there was no difference in
trabecular thickness. This suggests that proteoglycan 4 functions
to support the formation of distinct trabeculae during
endochondral bone formation, but does not effect the
remodeling of trabeculae. Based upon the findings that serum
P1NP and OCN were decreased, and there were no differences in
cortical bone or serum TRAP5b in young Prg4 mutant mice, we
speculate that the reduced number of trabeculae is associated
with decreased bone formation in young Prg4 mutant mice.
Fig. 6. Joint range of motion and animal mobility. (A–D) Sixteen-week-old Prg4 mutant (/) and wild-type (þ/þ) mice were administered intermittent
PTH(1–34) (50mg/kg) or vehicle (VEH) (0.9% NaCl) control subcutaneous injection daily for 6 weeks (‘‘adult’’ mice). (A,B) Maximal hind paw extension was
measured to assess joint range of motion. (A) Tibia was immobilized at 0 degrees and the maximal extension of the hind paw was measured. (B) Maximal
hind paw extension (n 5/group). p< 0.001 versus þ/þ VEH. (C,D) Spontaneous exploratory behavior was assessed to evaluate animal mobility. Mice
were placed in a 12-grid chamber for 1 minute; parameters assessed included number of grids crossed and number of hindlimb stands. (C) Number of
grids crossed (n 5/group). p< 0.01 versus þ/þ VEH. (D) Number of hindlimb stands (n 5/group). p< 0.05 versus þ/þ VEH. Data are expressed as
mean SEM.
Table 3. Real-Time PCR Analysis: Bone Marrow and Liver mRNA
þ/þ VEH þ/þ PTH / VEH / PTH
Adult Prg4 mice (n¼ 4–5/gp)
Marrow mRNA
PPR 1.00 0.19 0.84 0.06 0.77 0.08 0.64 0.05
IGF-I 1.00 0.03 0.80 0.05 0.89 0.09 0.68 0.04
FGF-2 1.00 0.08 1.01 0.05 0.68 0.06 0.91 0.08þ
Liver mRNA
PPR 1.00 0.08 0.98 0.14 0.68 0.06 0.86 0.09
IGF-I 1.00 0.14 1.02 0.13 0.59 0.06 1.03 0.07þþ
FGF-2 1.00 0.14 1.17 0.16 0.63 0.04 1.21 0.11þþ
gp¼group; PPR¼ PTH/PTHrP receptor; IGF-I¼ insulin-like growth
factor I; FGF-2¼ basic fibroblast growth factor 2. mRNA expression
was standardized to GAPDH levels, and relative quantification of data
generated was carried out using the comparative CT method. Data are
expressed as mean SEM.
p< 0.05 versus þ/þ VEH; þp< 0.05 versus / VEH,
þþp< 0.01 versus / VEH.
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Because BMSCs from Prg4 mutant mice were normal, proteogly-
can 4 actions supporting osteoblast-mediated formation of
trabeculae appear to be unique to the process of endochondral
bone formation. The lack of difference in bone cell numbers or
activity in the secondary spongiosa of adult Prg4 mutant mice
shows that proteoglycan 4 is not a critical regulator of skeletal
remodeling at trabecular sites in the mature skeleton. This
finding suggests that the trabecular bone osteopenic phenotype
in adult Prg4 mutant mice is likely secondary to proteoglycan 4
actions supporting endochondral bone formation.
Based on studies characterizing the role of FGF-2 in skeletal
development and remodeling, we speculate that the decreased
marrow and serum FGF-2 levels may play a role in the trabecular
bone osteopenia in Prg4 mutant mice. Exogenous FGF-2
administration stimulates endosteal and endochondral bone
formation in growing rats.(36) In adult rats, FGF-2 stimulates bone
formation at endosteal and trabecular bone surfaces,(37,38) and
has been shown to induce the formation of de novo bone
spicules within the marrow cavity.(37) FGF-2 is expressed in
differentiating growth plate chondrocytes, the centers of
ossification, and the calcified matrix,(39) which suggests that
FGF-2 plays a role in the formation of trabeculae during
endochondral bone formation. Bone marrow stromal/osteoblas-
tic cells secrete FGF-2(40,41) that signals to stromal/osteoblastic
cells in an autocrine/paracrine manner.(42,43) Whereas the liver
expresses FGF-2,(44,45) little is known regarding the role of the
liver in secreting FGF-2 into the circulation, or the impact of
circulating FGF-2 on the skeleton. Findings in the present study
suggest that liver-derived FGF-2 contributes to circulating levels
which impact skeletogenesis.
Similarities in the skeleton of Prg4 mutant and FGF-2 mutant
mice suggest that FGF-2 is a candidate regulator of proteoglycan
Table 4. Serum Biochemical Analysis: IGF-I and FGF-2
Adult Prg4 mice þ/þ VEH þ/þ PTH / VEH / PTH
Serum protein
IGF-I (ng/mL) (n¼ 4–5/gp) 603.19 28.78 589.78 7.38 538.29 32.52 554.81 24.79
FGF-2 (pg/mL) (n¼ 5–6/gp) 4.00 0.76 3.82 1.13 1.07 0.30 5.32 1.12þþ
gp¼ group; IGF-I¼ insulin-like growth factor I; FGF-2¼basic fibroblast growth factor 2. Data are expressed as mean SEM.
p< 0.01 versus þ/þ VEH; þþp< 0.01 versus / VEH.
Fig. 7. PTH regulation of bonemarrow and liver gene expression. (A–F) Sixteen-week-old Prg4mutant (/) and wild-type (þ/þ) mice were administered
a single subcutaneous injection of PTH(1–34) (1mg/g) or vehicle (VEH) (0.9% NaCl) control, euthanized 0 (no treatment control), 1, 4, 8, or 12 hours later,
and long bone marrow (n 5/group) and whole liver (n 5/group) harvested for gene expression analysis. RNA was isolated and quantitative real-time
PCR was performed to assess marrow; (A) PTH/PTHrP receptor (PPR), (B) insulin-like growth factor I (IGF-I), (C) basic fibroblast growth factor 2 (FGF-2), and
liver; (D) PPR, (E) IGF-I, ( F) FGF-2 mRNA expression (standardized to GAPDH levels). Relative quantification of data was determined using the comparative
CT method. Line graphs represent PTH effects on mRNA expression over time. (A) Marrow PPRmRNA; p< 0.05:þ/þ PTH versusþ/þ VEH; p< 0.05:/
PTH versus/ VEH. (B) Marrow IGF-I mRNA; p< 0.05:þ/þ PTH versusþ/þ VEH. (C) Marrow FGF-2mRNA; p< 0.05:þ/þ PTH versusþ/þ VEH; p< 0.01:
/ PTH versus/ VEH. (D) Liver PPRmRNA; p< 0.05:/ VEH versusþ/þ VEH; p< 0.05:þ/þ PTH versusþ/þ VEH; p< 0.01:/ PTH versus/
VEH. (E) Liver IGF-I mRNA; p< 0.05:/ VEH versusþ/þ VEH. ( F) Liver FGF-2 mRNA; p< 0.05:/ VEH versusþ/þ VEH; p< 0.05:þ/þ PTH versusþ/þ
VEH; p< 0.05: / PTH versus / VEH. Data are expressed as mean SEM.
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4 actions supporting the formation of numbers of trabeculae.
Whereas neither Prg4mutant or FGF-2 mutant mice exhibit gross
abnormalities in skeletal development or remodeling, both
models have significantly reduced trabecular bone in the
proximal tibia and distal femur sites that becomes more severe
with age.(31) Uniquely similar to the young and adult Prg4mutant
mice, 18-week-old FGF-2 mutant mice have decreased numbers
of trabeculae with increased trabecular separation, but no
difference in trabecular thickness.(31)
Although there are no known studies investigating the
osteogenic role of circulating FGF-2, based on studies showing
that circulating IGF-I has osteogenic effects separate from
marrow IGF-I,(16,22–25) we speculate that circulating FGF-2 may
have an important role in skeletal homeostasis and PTH skeletal
anabolism. Similar to the actions of PTH increasing serum FGF-2
levels in the osteopenic Prg4 mutant mice, intermittent PTH has
been reported to increase serum FGF-2 levels in osteoporotic
patients.(46) These data imply that the anabolic actions of PTH in
the osteopenic/osteoporotic skeleton are mediated at least in
part by an increase in circulating FGF-2.
Based on studies showing that exogenous FGF-2 does not
increase periosteal bone formation(36,47) and FGF-2 mutant mice
do not have reported abnormalities in cortical bone,(31) it does
not appear that the osteopenia of cortical bone in Prg4 mutant
mice is caused by the reduced FGF-2 levels. Because there were
no differences in cortical bone in the femur of young Prg4
mutant mice, the finding that cortical area fraction and cortical
thickness were decreased in the femur of adult Prg4mutant mice
indicates that proteoglycan 4 supports cortical bone homeosta-
sis in the mature remodeling skeleton. The increased endocor-
tical perimeter and marrow area associated with the decreased
cortical bone thickness in the femur of adult Prg4 mutant mice
suggests that endocortical resorption is occurring at amore rapid
rate than periosteal bone formation. Taking into consideration
that adult Prg4mutant mice had decreased joint range of motion
and animal mobility, it is likely that altered skeletal loading may
account for the cortical bone osteopenic phenotype. Similar to
the cortical bone osteopenia in adult Prg4 mutant mice, rodent
hindlimb immobilization studies have shown that cortical bone
disuse osteopenia is characterized by decreased cortical
thickness, increased endocortical perimeter, and expansion of
the marrow cavity.(48,49) Although we have proposed that the
trabecular bone osteopenia in adult Prg4 mutant mice is likely
secondary to altered endochondral bone formation, it is possible
that altered skeletal loading may contribute to the decreased
trabecular bone in adult Prg4 mutant mice.
Although there have been controversial findings from
investigations of PTH anabolic actions in rodent hindlimb
immobilization models, studies showing that loading is a critical
regulator of PTH actions increasing trabecular and cortical
bone(50,51) imply that the blunted PTH-induced increase in bone
in adult Prg4 mutant mice may be a result of compromised joint
function leading to altered skeletal loading. PTH has been
reported to restore lost trabecular bone in unloaded rats to the
levels of nontreated loaded controls,(50,51) which is similar to
what was seen in the present study in which PTH-treated adult
Prg4mutant mice had similar trabecular bone levels as untreated
wild-type mice. Similar to the lack of a PTH increase in cortical
bone in adult Prg4 mutant mice, PTH does not significantly
prevent cortical bone loss or restore lost cortical bone in
unloaded rats compared to the levels of nontreated loaded
controls.(50,52)
It is perplexing and not totally clear why adult Prg4 mutant
mice have a normal PTH anabolic response at the cellular level
(PTH increase in trabecular bone osteoblast numbers, osteoid
surface, osteoclast numbers, bone formation rate, and mineral
apposition rate) yet a blunted PTH anabolic response at the
tissue level (PTH increase in trabecular bone area and volume).
Rodent hindlimb immobilization studies of trabecular bone
disuse osteopenia have reported an acute phase, characterized
by increased bone resorption and decreased bone formation,
and a chronic phase during which bone cells re-equilibrate
and bone remodeling returns to physiologic levels.(53–55)
Taking into consideration that joint structure and function is
significantly disrupted in Prg4 mutant mice by 16 weeks of
age,(12,26) which appears to alter skeletal loading, we speculate
that adult Prg4mutant mice have a blunted tissue-level response
to PTH due a transient disruption of bone cell numbers and
actions (acute phase), which resolved by 22 weeks of age
(chronic phase).
Whereas there have been reports suggesting that the anabolic
actions of PTH on trabecular bone are independent of the level
of mechanical usage,(56,57) findings from the current study of
blunted PTH actions on trabecular bone in the compromised
joint status of the Prg4 mutant mice suggest that biomechanical
impact is a critical regulator of PTH anabolic actions. This study of
the effects of PTH in an animal model having precocious joint
failure raises the question of the efficacy of PTH anabolic therapy
in patients afflicted by arthropathic joint conditions that alter
skeletal loading.
The novel finding that PTH regulates PPR, FGF-2, and Prg4
mRNA expression similarly in bone and liver suggests that the
liver plays an important role in mediating the biologic actions of
PTH. Historically, PTH research has focused on the role of bone as
a mediator of PTH biologic actions. This focus is well grounded in
knowledge that stromal/osteoblastic cells are the predominant
cells in the body expressing the PPR, and PTH signaling in
stromal/osteoblastic cells regulates the local expression of
factors critical for the anabolic actions of PTH. In conjunction
with studies showing that the anabolic actions of PTH are
blunted in hepatocyte-specific IGF-I knockout models,(24,25) the
present study and work by Mitnick and colleagues,(58) which
show that PTH regulates liver gene and protein expression,
emphasize the need for investigations of the role of the liver as a
mediator of PTH biologic actions.
This original investigation of Prg4 actions in the skeleton
revealed that proteoglycan 4 is an important regulator of skeletal
development, remodeling, and PTH anabolic actions. Proteogly-
can 4 supports endochondral bone formation and the attain-
ment of peak trabecular bone mass in the developing skeleton.
In the mature remodeling skeleton, proteoglycan 4 appears to
indirectly support skeletal homeostasis and PTH anabolic actions
by protecting joint function. Bone- and liver-derived FGF-2
are candidate regulators of proteoglycan 4 actions supporting
the formation of trabeculae numbers. In summary, proteoglycan
4 is a dynamic factor supporting skeletogenesis and PTH
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skeletal anabolism via actions regulating trabecular bone
formation and protecting joint biomechanics. Finally, in addition
to well-characterized actions in osteoblasts, PTH likely impacts
skeletogenesis via actions in the liver.
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